Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches

References

• W.D. Shipe, S.S. Sharik, J.C. Barrow, G.B. McGaughey, C.R. Theberge, J.M. Uslaner, Y. Yan, J.J. Renger, S.M. Smith, P.J. Coleman, and C.D. Cox, Discovery and optimization of a series of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors through fragment screening, structure-based design, and parallel synthesis, J. Med. Chem. 58 (2015), pp. 7888–7894.
   PubMed Web of Science ®Google Scholar
• I.T. Raheem, M.J. Breslin, C. Fandozzi, J. Fuerst, N. Hill, S. Huszar, M. Kandebo, S.H. Kim, B. Ma, G. McGaughey, J.J. Renger, J.D. Schreier, S. Sharma, S. Smith, J. Uslaner, Y. Yan, P.J. Coleman, and C.D. Cox, Discovery of tetrahydropyridopyrimidinephosphodiesterase 10A inhibitors for the treatment of schizophrenia, Bioorg. Med. Chem. Lett. 15 (2012), pp. 5903–5908.
   Web of Science ®Google Scholar
• D.T. Manallack, R.A. Hughes, and P.E. Thompson, The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases, J. Med. Chem. 48 (2005), pp. 3449–3462.
   PubMed Web of Science ®Google Scholar
• F.S. Menniti, W.S. Faraci, and C.J. Schmidt, Phosphodiesterases in the CNS: Targets for drug development, Nat. Rev. Drug Discov. 5 (2006), pp. 660–670.
   PubMed Web of Science ®Google Scholar
• J. Kehler and J. Nielsen, PDE10A inhibitors: Novel therapeutic drugs for schizophrenia, Curr. Pharm. Des. 17 (2011), pp. 137–150.
   PubMed Web of Science ®Google Scholar
• J. Siuciak and C.A. Strick, Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia, Exp. Opin. Drug Discov. 2 (2007), pp. 1001–1009.
   PubMed Web of Science ®Google Scholar
• M. Rowley, L.J. Bristow, and P.H. Hutson, Current and novel approaches to the drug treatment of schizophrenia, J. Med. Chem. 44 (2001), pp. 477–501.
   PubMed Web of Science ®Google Scholar
• T.A. Chappie, C.J. Helal, and X. Hou, Current landscape of phosphodiesterase 10A (PDE10A) inhibition, J. Med. Chem. 55 (2012), pp. 7299–7331.
   PubMed Web of Science ®Google Scholar
• G.M. Rose, A. Hopper, M.D. Vivo, and A. Tehim, Phosphodiesterase inhibitors for cognitive enhancement, Curr. Pharm. Des. 11 (2005), pp. 3329–3334.
   PubMed Web of Science ®Google Scholar
• K. Fujishige, J. Kotera, and K. Omori, Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A, Eur. J. Biochem. 266 (1999), pp. 1118–1127.
   PubMedGoogle Scholar
• A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, V. Consonni, V.E. Kuz’min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richardand, and A. Tropsha, QSAR Modeling: Where have you been? Where are you going to? J. Med. Chem. 57 (2014), pp. 4977–5010.
   PubMed Web of Science ®Google Scholar
• C. Hansch, P. Maloney, T. Fujita, and R. Muir, Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients, Nature 194 (1962), pp. 178–180.
   Web of Science ®Google Scholar
• R.D. Cramer, The inevitable QSAR renaissance, J. Comput.-Aided. Mol. Des. 26 (2012), pp. 35–38.
   PubMed Web of Science ®Google Scholar
• N. Chirico and P. Gramatica, Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient, J. Chem. Inf. Model. 51 (2011), pp. 2320–2335.
   PubMed Web of Science ®Google Scholar
• N. Chirico and P. Gramatica, Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection, J. Chem. Inf. Model. 52 (2012), pp. 2044–2058.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modeling techniques, J. Biomol. Struct. Dyn. (2017) in press. doi: 10.1080/07391102.2017.1288659.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer and B. Wendt, Template CoMFA: The 3D-QSAR grail? J. Chem. Inf. Model. 54 (2014), pp. 660–671.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer and B. Wendt, Pushing the boundaries of 3D-QSAR, J. Comput.-Aided Drug Des. 21 (2007), pp. 23–32.
   PubMed Web of Science ®Google Scholar
• L.M. Shi, H. Fang, W. Tong, J. Wu, R. Perkins, R.M. Blair, W.S. Branham, S.L. Dial, C.L. Moland, and D.M. Sheehan, QSAR models using a large diverse set of estrogens, J. Chem. Inf. Comput. Sci. 41 (2000), pp. 186–195.
   Google Scholar
• J. Verma, V.M. Khedkar, and E.C. Coutinho, 3D-QSAR in drug design – A review, Curr. Top. Med. Chem. 10 (2010), pp. 95–115.
   PubMed Web of Science ®Google Scholar
• S. Kamath and J.K. Buolamwini, Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidenemalonitriletyrphostins as EGFR and HER-2 kinase inhibitors, J. Med. Chem. 46 (2003), pp. 4657–4668.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer and S. Shokouhi, Tabar, V.H. Masand, R. Aalizadeh, and M.R. Ganjali, 3D-QSAR and docking studies on adenosine A2A receptor antagonists by the CoMFA method, SAR QSAR Environ. Res. 26 (2015), pp. 461–477.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier protein, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, The role of 3D pharmacophore mapping based virtual screening for identification of novel anticancer agents: An overview, Curr. Top. Med. Chem. 13 (2013), pp. 1098–1126.
   PubMed Web of Science ®Google Scholar
• S. Ajmani, K. Jadhav, and S.A. Kulkarni, Three-dimensional QSAR using the k-nearest neighbor method and its interpretation, J. Chem. Inf. Model. 46 (2006), pp. 24–31.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, TopomerCoMFA: A design methodology for rapid lead optimization, J. Med. Chem. 16 (2003), pp. 374–388.
   Web of Science ®Google Scholar
• S. Yu, J. Yuan, J. Shi, X. Ruan, T. Zhang, Y. Wang, and Y. Du, HQSAR and topomerCoMFA for predicting melanocortin-4 receptor binding affinities of trans-4-(4-chlorophenyl) pyrrolidine-3-carboxamides, Chemometr. Intell. Lab. Syst. 146 (2015), pp. 34–41.
   Web of Science ®Google Scholar
• C. Xu and Y. Ren, Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, TopomerCoMFA, molecular docking and molecular dynamics simulations, Bioorg. Med. Chem. Lett. 25 (2015), pp. 4522–4528.
   PubMed Web of Science ®Google Scholar
• M. Dong and Y. Ren, Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, TopomerCoMFA and molecular docking simulations, RSC Adv. 5 (2015), pp. 13754–13761.
   Google Scholar
• E. Pourbasheer, R. Aalizadeh, S.S. Tabar, M.R. Ganjali, P. Norouzi, and J. Shadmanes, 2D and 3D-QSAR study of Hepatitis C Virus NS5B polymerase inhibitors by CoMFA and CoMSIA methods, J. Chem. Inf. Model. 54 (2014), pp. 2902–2914.
   PubMed Web of Science ®Google Scholar
• S.P. Kumar, P.C. Jha, Y.T. Jasrai, and H.A. Pandya, The effect of various atomic partial charge schemes to elucidate consensus activity-correlating molecular regions: A test case of diverse QSAR models, J. Biomol. Struct. Dyn. 34 (2016), pp. 540–559.
   PubMed Web of Science ®Google Scholar
• S.K. Verma and S. Thareja, Molecular docking assisted 3D-QSAR study of benzylidene-2,4-thiazolidinedione derivatives as PTP-1B inhibitors for the management of Type-2 diabetes mellitus, RSC Adv. 6 (2016), pp. 33857–33867.
   Web of Science ®Google Scholar
• S.S. Bhayye, K. Roy, and A. Saha, Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors, SAR QSAR Environ. Res. 27 (2016), pp. 183–202.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer and R. Aalizadeh, 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods, SAR QSAR Environ. Res. 27 (2016), pp. 385–407.
   PubMed Web of Science ®Google Scholar
• S. Liu, Y. Luo, J. Fu, J. Zhou, and G.Z. Kyzas, Molecular docking and 3D-QSAR studies on the glucocorticoid receptor antagonistic activity of hydroxylated polychlorinated biphenyls, SAR QSAR Environ. Res. 27 (2016), pp. 87–99.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, A.C. Shinde, M.K. Sharma, H. Yamaguchi, P.B. Miniyar, and M.R. Yadav, Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors, SAR QSAR Environ. Res. 27 (2016), pp. 265–292.
   PubMed Web of Science ®Google Scholar
• J. Andrades, J. Campanini, D. Vásquez, C. Silvestri, C. Morales, J. Romero, and J. Mella, A combined CoMFA and CoMSIA 3D-QSAR study of benzamide type antibacterial inhibitors of the FtsZ protein in drug-resistant Staphylococcus aureus, SAR QSAR Environ. Res. 26 (2015), pp. 925–942.
   PubMed Web of Science ®Google Scholar
• J. Sainy and R. Sharma, QSAR analysis of thiolactone derivatives using HQSAR, CoMFA and CoMSIA, SAR QSAR Environ. Res. 26 (2015), pp. 873–892.
   PubMed Web of Science ®Google Scholar
• P.R. Murumkar, V.P. Zambre, and M.R. Yadav, Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors, J. Comput. Aided Mol. Des. 24 (2010), pp. 143–156.
   PubMed Web of Science ®Google Scholar
• C. Mondal, A.K. Halder, N. Adhikari, and T. Jha, Structural findings of cinnolines as anti-schizophrenic PDE10A inhibitors through comparative chemometric modelling, Mol. Divers. 18 (2014), pp. 655–671.
   PubMed Web of Science ®Google Scholar
• C. Mondal, A.K. Halder, N. Adhikari, A. Saha, K.D. Saha, S. Gayen, and T. Jha, Comparative validated molecular modeling of p53–HDM2 inhibitors as antiproliferative agents, Eur. J. Med. Chem. 90 (2015), pp. 860–875.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Exploring structural requirements of unconventional Knoevenagel-type indole derivatives as cytotoxic agents through comparative QSAR modeling approaches, Can. J. Chem. 94 (2016), pp. 637–644.
   Web of Science ®Google Scholar
• P. Tosco and T. Balle, Open3DQSAR: A new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields, J. Mol. Model. 17 (2011), pp. 201–208.
   PubMed Web of Science ®Google Scholar
• SYBYL-X 2.0. Tripos, St. Louis, 2015; software available at http://www.certara.com.
   Google Scholar
• VLifeMDS 4.4 software, Vlife Sciences Technologies Pvt. Ltd. Pune, India, 2015; software available at http://www.vlifesciences.com.
   Google Scholar
• Discovery Studio 3.0 (DS 3.0), Accelrys Inc., San Diego, USA, 2015; software available at http://www.accelrys.com.
   Google Scholar
• P. Tosco, T. Balle, and F. Shiri, Open3DALIGN: An open-source software aimed at unsupervised ligand alignment, J. Comput. Aided Mol. Des. 25 (2011), pp. 777–783.
   PubMed Web of Science ®Google Scholar
• S.A. Amin and S. Gayen, Modeling cytotoxic activity of some pyrazolo-triazole hybrids using descriptors calculated from open source tool "PaDEL-descriptor", J. Taibah Univ. Sci. 10 (2016), pp. 896–905.
   Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, Insight into the structural requirements of theophylline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors through multi-QSAR modeling and molecular docking approaches, Curr. Drug Design Tech. 13 (2016), pp. 84–100.
   PubMedGoogle Scholar
• Protein Data Bank. Available at http://www.rcsb.org/pdb/home/home.do (accessed June 15, 2016).
   Google Scholar
• ChemDraw Ultra 8.0, Cambridge Soft Corporation, USA, 2015; software available at http://www.cambridgesoft.com.
   Google Scholar
• T.A. Halgren, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94, J. Comp. Chem. 17 (1996), pp. 490–519.
   Web of Science ®Google Scholar
• S.D. O’Connor, P.E. Smith, F. Al-Obeidi, and B.M. Pettitt, Quenched molecular dynamics simulations of tuftsin and proposed cyclic analogs, J. Med. Chem. 35 (1992), pp. 2870–2881.
   PubMed Web of Science ®Google Scholar
• N.J. Richmond, P. Willett, and R.D. Clark, Alignment of three-dimensional molecules using an image recognition algorithm, J. Mol. Graph Model. 23 (2004), pp. 199–209.
   PubMed Web of Science ®Google Scholar
• J. Taminau, G. Thijs, and H. De Winter, Pharao: Pharmacophore alignment and optimization, J. Mol. Graph Model. 27 (2008), pp. 161–169.
   PubMed Web of Science ®Google Scholar
• J. Gasteiger and M. Marsili, Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges, Tetrahedron 36 (1980), pp. 3219–3228.
   Web of Science ®Google Scholar
• M. Pastor, G. Cruciani, and S. Clementi, Smart Region Definition: A new way to improve the predictive ability and interpretability of three-dimensional quantitative structure activity relationships, J. Med. Chem. 40 (1997), pp. 1455–1464.
   PubMed Web of Science ®Google Scholar
• M. Baroni, S. Clementi, G. Cruciani, G. Costantino, and D. Riganelli, Predictive ability of regression models. Part II: Selection of the best predictive PLS model, J. Chemom. 6 (1992), pp. 347–356.
   Web of Science ®Google Scholar
• V. Centner, D.L. Massart, O.E. de Noord, S. de Jong, B.M. Vandeginste, and C. Sterna, Elimination of uninformative variables for multivariate calibration, Anal. Chem. 68 (1996), pp. 3851–3858.
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System, Version 1.7.0.4, Schrodinger, LLC, USA; software available at http://www.pymol.org.
   Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
   PubMed Web of Science ®Google Scholar
• V. Consonni, D. Ballabioand, and R. Todeschini, Comments on the definition of the Q2 parameter for QSAR validation, J. Chem. Inf. Model. 49 (2009), pp. 1669–1678.
   PubMed Web of Science ®Google Scholar
• R. Wehrens, H. Putter, and L.M.C. Buydens, The bootstrap: A tutorial, Chemometr. Intell. Lab. Syst. 54 (2000), pp. 35–52.
   Web of Science ®Google Scholar
• G. Folkers, A. Merz, and D. Rognan, Theory methods and applications, in 3D-QSAR in Drug Design, H. Kubinyi, ed., ESCOM, Leiden, the Netherlands, 1994, pp. 583–618.
   Google Scholar